



بسم الله الرحمن الرحيم

∞∞∞∞

تم رفع هذه الرسالة بواسطة / مني مغربي أحمد

بقسم التوثيق الإلكتروني بمركز الشبكات وتكنولوجيا المعلومات دون أدنى

مسئولية عن محتوى هذه الرسالة.

ملاحظات: لا يوجد





Assessment of the Serum Ischemia Modified Albumin Level and its Relation to Total Oxidant Status and Disease Activity in Vitiligo Patients

Thesis

*Submitted for Fulfillment of Master Degree
in Dermatology, Venereology and Andrology*

Presented By

Nada Ahmed Abdo Elzainy

M.B.B.Ch.

Faculty of Medicine, Ain Shams University

Under Supervision of

Prof. Dr. Hanan Mohammed Saleh

Professor of Dermatology, Venereology and Andrology

Faculty of Medicine, Ain Shams University

Assist. Prof. Dr. Marwa Yassin Soltan

Assistant Professor of Dermatology, Venereology and Andrology

Faculty of Medicine, Ain Shams University

*Faculty of Medicine
Ain Shams University*

2022

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

سُبْحَانَكَ لَا عِلْمَ لَنَا
إِلَّا مَا عَلَّمْتَنَا إِنَّكَ أَنْتَ
الْعَلِيمُ الْعَظِيمُ

صدق الله العظيم

سورة البقرة الآية: ٣٢

Acknowledgments

*First and foremost, I feel always indebted to **Allah** the Most Beneficent and Merciful.*

*I'd like to express my respectful thanks and profound gratitude to **Prof. Dr. Hanan Mohammed Saleh**, Professor of Dermatology, Venereology and Andrology - Faculty of Medicine- Ain Shams University for his keen guidance, kind supervision, valuable advice and continuous encouragement, which made possible the completion of this work.*

*I am also delighted to express my deepest gratitude and thanks to **Dr. Marwa Yassin Soltan**, Assistant Professor of Dermatology, Venereology and Andrology, Faculty of Medicine, Ain Shams University, for his kind care, continuous supervision, valuable instructions, constant help and great assistance throughout this work.*

Nada Ahmed Abdo Elzainy

List of Contents

Title	Page No.
List of Tables.....	i
List of Figures	ii
List of Abbreviations	iv
1. Introduction	1
2. Aim of the Work.....	3
3.1. Vitiligo.....	4
3.1.1. Prevalence:	4
3.1.2. Pathogenesis:.....	4
3.1.3. Clinical picture:	10
3.1.4. Diagnosis:	16
3.1.5. Histopathology and immuno-histochemistry:.....	17
3.1.6. Differential Diagnosis:	17
3.1.7. Investigations:.....	19
3.1.8. Vitiligo Assessment:.....	20
3.1.10. Treatment:.....	24
3.2. Oxidative Stress in Vitiligo	34
3.2.1. Oxidative stress role in pathogenesis of vitiligo:	34
3.2.2. Interlacement of oxidative stress with other etiopathogenesis of vitiligo:.....	35
3.2.3. Epidermal cells redox homeostasis:	36
3.2.4. Markers of oxidative stress in vitiligo:.....	37
3.3. Ischemia Modified Albumin (IMA)	43
3.3.1. What is IMA?.....	43
3.3.2. Clinical perspectives on IMA:.....	44

List of Contents *cont...*

Title	Page No.
3.3.3. IMA role in dermatology:.....	44
3.3.4. IMA in predicting oxidative stress in vitiligo:	45
3.3.5. Assessment of IMA level:	46
4. Patients and Methods.....	48
5. Results.....	59
6. Discussion	75
7. Summary.....	84
8. Conclusion and Recommendation	87
9. References	89
10. Arabic Summary	91

List of Tables

Table No.	Title	Page No.
Table 1:	Socio-demographic characteristics of the study participants.....	60
Table 2:	The clinical characteristics of vitiligo disease among the included patients.....	62
Table 3:	Comparison between control and patients groups regarding TOS level and IMA level.	63
Table 4:	ROC curve for IMA and TOS levels in detection of vitiligo disease.	66
Table 5:	Comparison between active and non-active cases according to IMA Level (ng/ml) and TOS Level ($\mu\text{mol H}_2\text{O}_2$ Eq/L) in patients group.	68
Table 6:	Validity of IMA and TOS levels in detection of vitiligo activity.....	71
Table 7:	Correlation between TOS Level ($\mu\text{mol H}_2\text{O}_2$ Eq/L) and IMA level (ng/ml) with VIDA Score and VETI score among patient group.....	72

List of Figures

Fig. No.	Title	Page No.
Figure 1:	Focal vitiligo	13
Figure 2:	Mucosal vitiligo.....	13
Figure 3:	Segmental vitiligo.....	14
Figure 4:	Acrofacial Vitiligo	14
Figure 5:	Vitiligo vulgaris	15
Figure 6:	Universal vitiligo	15
Figure 7:	Wood's light examination showing accentuated lesions by Wood's light	16
Figure 8:	Differential Diagnosis of Vitiligo	18
Figure 9:	Guttate Leucoderma.....	19
Figure 10:	Rule of nines in burn assessment	23
Figure 11:	N-terminus binding site of albumin	43
Figure 12:	Albumin-cobalt binding test.....	46
Figure 13:	Boxplot chart showing the significantly high levels of IMA levels in cases compared to controls.....	64
Figure 14:	Boxplot chart showing the significantly high levels of TOS in cases compared to controls.....	64
Figure 15:	Receiver Operating Characteristic curve (ROC) for TOS and IMA serum levels differentiation between cases and contols:.....	66
Figure 16:	A boxplot chart showing the increased IMA levels in active cases compared to non-active cases.	69
Figure 17:	A boxplot chart showing the increased TOS levels in active cases compared to non-active cases.	69

List of Figures cont...

Fig. No.	Title	Page No.
Figure 18:	Receiver Operating Characteristic curve (ROC) for TOS and IMA serum levels between active vitiligo patients and non-active vitiligo cases.	71
Figure 19:	Scatter dot curve demonstrating the positive correlation between IMA and TOS serum levels.	73
Figure 20:	Scatter dot curve demonstrating positive relation between IMA serum levels and VIDA score.	73
Figure 21:	Scatter dot curve demonstrating positive relation between TOS serum levels and VIDA score.	74

List of Abbreviations

Abb.	Full term
ABSU	Absorbance units
ACB	Albumin-cobalt binding
ANA	Antinuclear antibodies
ASDB	Amelanotic with sharply demarcated borders
AUC	Area under curve
bFBGF	Basic fibroblast growth factor
BMI	Body mass index
BSA.....	Body surface area
CAT	Catalase
CD8+	Cytotoxic T cell
CoCl ₂	Cobalt ions
DAMPs	Damage-associated molecular patterns
DOPA	Dihydroxyphenylalanine
DTT	Dithiothreitol
ELISA.....	Enzyme-Linked Immunosorbent Assay
ET-1.....	Endothelial 1
FDA	Food and drug administration
GSH.....	Glutathione
GSH-PX	Glutathione peroxidase
H ₂ O ₂	Hydrogen peroxide
HMB-45.....	Human melanoma black-45
HPDB	Hypomelanotic with poorly defined borders
HS	Highly significant
IMA	Ischemia Modified Albumin
INF- γ	Interferon gamma
IQR	Inter-quartile range
MBEH	Monobenzylether of hydroquinone
MDA	Malondialdehyde
MF	Masson Fontana stain
MHC2.....	Major histocompatibility complex 2
NCES	Non cultured epidermal suspension
NO	Nitric oxide
NPs	Neuro-peptides
NPV	Negative predictive value

List of Abbreviations *cont...*

Abb.	Full term
NPY	Neuro-peptide Y
NS	Non significant
NSV	Non segmental vitiligo
O.D	Optical indensity
O2-.....	Superoxide anion
OMP	Oral mini-pulse
PPV	Positive predictive value
PUFA	Polyunsaturated fatty acid
PUVA	Psoralen plus UVA
QOL	Quality of life assessment
ROC	Receiver operating characteristic curve
ROS	Reactive oxygen species
S	Significant
SCF	Stem cell factor
SNPs.....	Single nucleotide polymorphisms
SOD	Super-oxide dismutase
SPSS	Statistical Package for Social Science
TAS.....	Total antioxidant status
TCI	Topical calcineurin inhibitors
TLR.....	Toll like receptor
TOS	Total Oxidant Status
Tregs.....	Regulatory T cells
VASI	Vitiligo Area Scoring Index
VETF	Vitiligo European Task Force Assessment
VETI	Vitiligo Extent Tensity Index
VIDA Score	Vitiligo Disease Activity Score

1. INTRODUCTION

Vitiligo is an acquired depigmentary skin disorder characterized by loss of functioning epidermal melanocytes. It occurs worldwide. Both genders and all races are affected (*Bergqvist et al., 2020*).

The etiopathogenesis of vitiligo is complex and unclear. Several etiological factors have been suggested such as autoimmune mechanism, genetic and environmental factors (*Furue et al., 2016*).

Among the etiological factors, oxidative stress can directly disturb melanin metabolism and undermine melanocyte survival through excessive accumulation of cytotoxic hydrogen peroxide. Oxidative stress may play an essential role in activating subsequent autoimmune responses related to vitiligo (*Xie et al., 2015*).

Reactive oxygen species (ROS) which are induced by multifactorial process and in conjunction with the impaired antioxidant defenses, lead to the loss of melanocyte redox homeostasis, and therefore, the stressed melanocytes generate damage-associated molecular patterns (DAMPs) or auto-antigens then initiate innate immunity and adaptive immunity, leading to the dysfunction and death of melanocytes (*Wang et al., 2019*).

High levels of reactive oxidative species (ROS) are observed in patients with active vitiligo, this is probably correlated with increased intracellular ROS production in the tissue of these patients

(*Ines et al., 2009*). *Akoglu et al. (2013)* found that total oxidant status serum levels (TOS) were higher and total antioxidant status serum levels (TAS) were lower in patients with vitiligo than in controls.

Ischemia-modified albumin (IMA) is a new biomarker for ischemia (*Hatice et al., 2017*). As in ischemic status, albumin loses binding capacity and the ability of transition metals on the N-terminal ends. A high level of IMA is also detected in diseases related to oxidative stress, such as psoriasis, vascular injury of diabetes mellitus, multiple sclerosis, some cancers, acute appendicitis, polycystic ovary syndrome and β -thalassemia major (*Ahmad et al., 2016*).

Ischemia-modified albumin (IMA) has been described as a biomarker of oxidative stress and extensively investigated recently (*Shevtsova et al., 2021*). *Ozdemir et al. (2012)* noted that IMA could be produced as an adaptive response to chronic hypoxia and oxidative stress. It has been shown that IMA had a strong predictive power, the sensitivity, specificity, capacity, and positive and negative predictive values of IMA were detected to be higher than other studied biomarkers of oxidative stress (*Ataş et al., 2017*).

In the view that oxidative stress has been linked to vitiligo pathogenesis and disease activity, IMA was detected to be higher in patients with vitiligo, we thought to investigate the serum level of IMA in vitiligo patients and its possible relation to TOS levels and disease activity.

2. AIM OF THE WORK

The aim of this work was to evaluate the serum level of ischemia modified albumin in vitiligo patients and its relation to total oxidant status and disease activity.

Chapter 1

3.1. VITILIGO

Vitiligo is a chronic acquired disease characterized by appearance of circumscribed achromatic macules to patches often associated with leukotrachia in various parts of body, due to progressive destruction and reduction in numbers of melanocytes (*Varzhapetyan et al., 2019*).

3.1.1. Prevalence:

The prevalence of vitiligo worldwide ranges from 0.5% to 2% of general population without clear preference for race or sex, although women may be more likely to present for treatment because of cosmetic reasons and respond to surveys (*Bergqvist et al., 2020*).

3.1.2. Pathogenesis:

3.1.8.1. Genetic:

Various studies have found that the frequency of vitiligo among 1st degree relatives varies from 0.14% to as high as 20%, this suggests strong familial tendency (*Alkhateeb et al., 2003*).

Vitiligo is a poly-genetic disorder. A large scale genome studies have discovered approximately 50 different genetic loci that contribute to vitiligo risk, a large fraction of these genes encode proteins involved in immune regulation, cellular apoptosis and regulation functions of melanocytes (*Spritz et al., 2017*).